<DOC>
	<DOCNO>NCT02005757</DOCNO>
	<brief_summary>The purpose study access efficacy safety Mizoribine 150mg qid 50mg tid active rheumatoid arthritis patient unsuccessfully treat disease-modifying antirheumatic drug .</brief_summary>
	<brief_title>Efficacy Safety Study Mizoribine Active Rheumatoid ( AMOLED )</brief_title>
	<detailed_description>1 . EULAR Response 24weeks treatment 2 . EULAR Response 12weeks treatment 3 . DAS28 value change 4 . KHAQ-20 value change</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Bredinin</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Male female age 20 80 year old Signed date informed consent document indicate patient Patients must diagnosis Rheumatoid Arthritis ( RA ) least 3months duration define 2010 American College Rheumatology ( ACR ) Classification criterion . Patients Disease Activity Score 28 great equal 3.2 ( DAS28 ≥ 3.2 ) receive treatment 1 kind diseasemodifying antirheumatic drug ( include MTX ) . ESR≥28mm/h CRP≥1.0mg/dl screen . Exclusion Criteria At screening , patient laboratory result define : white blood cell ≤ 3,000/mm3 , Hemoglobin &lt; 8.5 g/dL , Platelet count &lt; 100,000/mm3 , Serum creatinine &gt; 2.0 mg/dL , Aspartic Acid Transaminase/Alanine Transaminase ≥ 2*upper limit normal , Uric acid ≥ 1.5*upper limit normal Patient must bleed disorder take anticoagulant . ( But , lt allow take 100mg/day Asprin ) Patients history operation index knee joint could influence result need surgery determine investigator . Patients severe infection , include moderate respiratory disease receive treatment systemic antibiotic within 2 week . Patients cardiovascular disease associate disease control . Patients history malignancy within 5years . ( But , basal cell squamous cell carcinoma carcinoma situ uterine cervix treat allow ) Patients hypersensitivity reaction drug . Patients clinical trial experimental treatment past 3months . Female patient breast feeding , pregnant plan become pregnant trial two month follow study termination . Not allowable medication record ; Intraarticular injection within week baseline visit , Patients take oral steroid 10mg /day use new treatment change dosage within 4weeks baseline visit , Using new nonsteroidal antiinflammatory drug within 4 week change nonsteroidal antiinflammatory drug dosage within 2 week baseline visit . Having experience use biologic agent , immunosuppressant , cytostatic preparation within 8weeks baseline visit . ( But , Rituximab allow within 6months ) Start treatment new diseasemodifying antirheumatic drug need change dosage diseasemodifying antirheumatic drug take trial . ( Leflunomide ( ARAVA® ) allow within 12weeks , But , Cholestyramine allow 48 hour later stop . use three time day , 8g , 11days )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>Mizoribine</keyword>
	<keyword>DAS28</keyword>
	<keyword>European League Against Rheumatism</keyword>
</DOC>